MDxHealth expects to be key Dutch provider of urine-based prostate cancer testing
This article was originally published in Clinica
Executive Summary
MDxHealth has launched a new liquid biopsy prostate cancer test, SelectMDx, in Europe, a month after gaining the technology through the acquisition of its developer NovioGendix. The test will be offered through NovioGendix’s lab facilities in Nijmegen, the Netherlands, which MDxHealth also acquired.